ETRA
Electra Therapeutics, Inc. · Healthcare
Insiders bought $40.0M of Electra Therapeutics, Inc. in the last 12 months
2 insiders bought on 1 day.
ETRA over the last year
Largest buyers, last 12 months
ETRA after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Every filing
2 insider filings since 2026, newest first
About Electra Therapeutics, Inc.
Electra Therapeutics, Inc. is a clinical-stage biotechnology company. It develops therapies that target signal regulatory proteins for the treatment of novel targets for diseases in immunology and cancer. Its product, ELA026, is a monoclonal antibody that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professionals to find an approved treatment for secondary hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory condition. The company was incorporated in 2018 and is based in South San Francisco, California.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.